title: Endonuclease mediated genome editing in drug discovery and development: promises and challenges.
abstract: Site specific genome editing has been gradually employed in drug discovery and development process over the past few decades. Recent development of CRISPR technology has significantly accelerated the incorporation of genome editing in the bench side to bedside process. In this review, we summarize examples of applications of genome editing in the drug discovery and development process. We also discuss current hurdles and solutions of genome editing.
authors.affiliation: Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA 91320, USA.
authors.forename: Vidya
authors.initials: V
authors.lastname: Prabhu
authors.affiliation: Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA 91320, USA. Electronic address: hanx@amgen.com.
authors.forename: Han
authors.initials: H
authors.lastname: Xu
mesh_terms: D000818:Animals; D055808:Drug Discovery; D004720:Endonucleases / Q000235:genetics*; D000072669:Gene Editing / Q000266:history; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans
chemical_list: D004720:Endonucleases